

## Certificate of Analysis

### IRR, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-645, 14-645-K, 14-645M

Parent Lot # 1980269

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal 6His-tagged, recombinant, human IRR, amino acids 944–1266 expressed by baculovirus in Sf21 insect cells. Purified using Ni<sup>2+</sup>-NTA agarose. Purity 71.2% by SDS PAGE and Coomassie blue staining. MW = 37.9kDa.

**Specific Activity (Parent lot# 1980269):** 42U/mg, where one unit of IRR, active activity is defined as 1nmol phosphate incorporated into 0.33mg/ml myelin basic protein (MBP) per minute at 30°C with a final ATP concentration of 100µM.

**Formulation:** 0.566mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 210–472ng of this lot of enzyme phosphorylated 0.33mg/ml myelin basic protein (MBP) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed product identity as IRR with the translated native sequence listed on page three.



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Myelin basic protein (MBP):** Use at a final assay concentration of 0.33mg/ml. Make up a 3.3mg/ml stock. Use 2.5µl of stock per assay point.
3. **IRR, active:** Dilute with 20mM MOPS/NaOH pH 7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 210–472ng per assay point.
4. **[ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required).

#### Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells.
2. Add 2.5µl of **myelin basic protein (MBP)**.
3. Add **2.5µl (210–472ng) IRR, active**.
4. Add 5µl of dH<sub>2</sub>O.
5. Add 10µl of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

# Certificate of Analysis

## IRR Sequence Information

|                                |                                                                      |
|--------------------------------|----------------------------------------------------------------------|
| <b><u>Protein</u></b>          | human IRR                                                            |
| <b><u>Tags</u></b>             | N-terminal 6His                                                      |
| <b><u>Native sequence</u></b>  | F9 of recombinant sequence is equivalent to F943 of native human IRR |
| <b><u>Accession number</u></b> | GenBank NM_014215                                                    |

### Recombinant IRR amino acid sequence:

```

1  MHHHHHHEFY GKRNRTLYA SVNPEYFSAS DMYVPDEWEV PREQISIIRE LGQGSFGMVY
61  EGLARGLEAG EESTPVALKT VNELASPREC IEFLKEASVM KAFKCHHVVR LLGVVSQGGP
121 TLVIMELMTR GDLKSHLRSL RPEAENNPGL PQPALGEMIQ MAGEIADGMA YLAANKFVHR
181 DLAARNCMVS QDFTVKIGDF GMTRDVYETD YYRKGGKGLL PVRWMAPEL KDGIPTTHSD
241 VWSFGVVLWE IVTLAEQPYQ GLSNEQVLKF VMDGGVLEEL EGCPLQLQEL MSRCWQPNPR
301 LRPSFTHILD SIQEELRPSF RLLSFYYSPE CR

```

### Recombinant IRR nucleotide sequence:

```

1  atgcatcatc accatcacca tgaattctac ggcaagaaga gaaacagaac cctgtatgct
61  tctgtgaatc cagagtactt cagcgctctt gatatgtatg tccctgatga atgggagggtg
121 cctcgggagc agatctcgat aatccgggaa ctgggccagg gctcttttgg gatggtatat
181 gaggggctgg caccaggact tgaggctgga gaggagtcca caccctggc cctgaagacg
241 gtgaatgagc tggccagccc acgggaatgc attgagttcc tcaaggaagc ttctgtcatg
301 aaagccttca agtgtcacca tgtgtgctgt ctcctgggtg tggatatctca gggccagcca
361 actctggtca tcatggagtt aatgaccgtg ggggacctca agagccatct tcgatctttg
421 cggcctgagg cagagaacaa ccctgggctc ccacagccag cattggggga aatgatccaa
481 atggctggtg agattgcaga cggcatggcc taccttgctg ccaacaagtt tgtgcaccga
541 gatctagcag cccgcaactg catggtgtcc caggacttca ccgtcaagat cggggacttc
601 gggatgactc gggacgtgta tgagacagac tattaccgca aggggtggga ggggctgctg
661 cccgtgctgt ggatggcccc cgagtcctc aaagatggga tcttcaccac ccactcggtg
721 gtctggctct ttggcgtggt actctgggag attgtgacct tggcagaaca accctaccag
781 ggcctgtcca atgagcaggt gctgaagttc gtcattggat gcggggctct ggaggagctg
841 gagggctgtc cccttcagct gcaggagctg atgagccgct gctggcagcc gaaccacgc
901 ctgcgcccac ctttcacaca cattctggac agcatacagg aggagctgct gccctccttc
961 cgctcctct ctttacta cagccggaa tgccggtaa

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services